### ICMJE DISCLOSURE FORM

Date:20 Sept 2021		
Your Name:Aina Pons		
Manuscript Title: Thoracic Surgery in the UK		
Manuscript number (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	T.	Time frame: Since the initial	planning of the work
1	All support for the present	xNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	xNone	
4	Consulting fees	xNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	xNone
7	Support for attending meetings and/or travel	x_None
8	Patents planned, issued or pending	xNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	xNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x_None
11	Stock or stock options	x_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	x_None
13	Other financial or non- financial interests	x_None

## Please summarize the above conflict of interest in the following box:

None

Please place an "X" next to the following statement to indicate your agreement:

\_x\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

Date:	9/14/2021
Your Name:	Eric Lim
Manuscript Title:	Thoracic Surgery in the UK
Manuscript Number (if known):	JTD-21-1080

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		
1	All support for the present		
	manuscript (e.g.,	Johnson and Johnson / Ethicon	Me
	funding, provision	Covidien / Medtronic	Me
	of study materials,	Guardant Health	My institution
	medical writing, article processing charges, etc.) No time limit for this item.		
	Time frame: past 36 months		
2	Grants or contracts from	□ None	
	any entity (if not	AstraZeneca	Me
	indicated in item	Boehringer Ingelheim	Me
	#1 above).	Medela	Me / my institution
		Lilly	Me

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	None   Beigene   Roche   BMS	Me Me Me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Medela	Me
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	None       P52435GB       P57988GB	Imperial Innovations Imperial Innovations
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑ None	
10	Leadership or fiduciary role in other board,	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-financial interests	NoneVIOLET NIHR HTA (13/04/03)MARS 2 NIHR HTA (15/188/31)RAMON NIHR HTA (131306)My Cancer Companion,Healthcare Companion Ltd	Chief investigator Chief investigator Chief investigator Founder

### Please summarize the above conflict of interest in the following box:

Outside this work, Prof. Lim reports personal fees from Abbott Molecular, personal fees from Glaxo Smith Kline, personal fees from Pfizer, personal fees from Norvatis, personal fees from Medtronic / Covidien, personal fees from Roche, personal fees from Lily Oncology, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Medela, grants and personal fees from ScreenCell, personal fees from Johnson and Johnson / Ethicon, grants from Clearbridge Biomedics, grants from Illumina, grants from Guardant Health, grants and personal fees from AstraZeneca, personal fees from BMS, outside the submitted work; In addition, Dr. Lim has a patent P52435GB issued to Imperial Innovations, and a patent P57988GB issued to Imperial Innovations and CI for VIOLET NIHR HTA (13/04/03), CI for MARS 2 NIHR HTA (15/188/31), CI for RAMON NIHR HTA (131306). Founder of My Cancer Companion and Healthcare Companion Ltd.+

#### Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.